Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.40 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
49 50 Next >
AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer
The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) cancer drug, jointly developed with Merck & Co Inc (NYSE: MRK) to treat patients with early-... 
Via Benzinga
Upcoming Stock Splits 2022: 20 Companies That Could Follow Amazon’s Lead
We're taking a gander at more companies that could follow Amazon's (AMZN) lead with potential upcoming stock splits in 2022. 
Via InvestorPlace
How A Mixed Breast Cancer Study Cast Doubt On Gilead's Immunomedics Buyout
Gilead's Trodelvy had mixed test results in patients with breast cancer. 
Via Investor's Business Daily
Merck (MRK) Outperforms Industry, What's In Store For 2022?
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. 
Via Talk Markets
AstraZeneca-Sanofi's Nirsevimab Shows 75% Efficacy Against RSV In Healthy Infants
AstraZeneca Plc (NASDAQ: AZN) and Sanofi SA (NASDAQ: SNY) have shared detailed results from the MELODY Phase 3 trial evaluating nirsevimab in respiratory... 
Via Benzinga
AstraZeneca, GSK's COVID-19 Therapies Lose Efficacy Against Omicron's Subvariants
The FDA authorized an increased dose in the case of AstraZeneca Plc's (NASDAQ: AZN) pre-exposure prophylaxis drug Evusheld (tixagevimab and cilgavimab).... 
Via Benzinga
Stock Market Tumbles, Rebounds As Russia Invades Ukraine: Weekly Review
The stock market fell back into a correction, but is trying to rally back. 
Via Investor's Business Daily
Red Ink
There is little joy in stocks today as even companies reporting good results are being hit by fear of Ukraine sanctions.tbph 
Via Talk Markets
4 Pharma Stocks to Buy Even if the Pandemic Ends
Here are four pharma stocks that looks attractive for the long-term. Deep product development pipelines will ensure steady revenue and cash flow growth. 
Via InvestorPlace
Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows
A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found between one and three cases per million, and only after... 
Via Benzinga
7 Safe Stocks to Buy If You Fear the Bear
Safe stocks tend to perform well no matter what the broader market does. Here are seven defensive companies to research further. 
Via InvestorPlace
AstraZeneca Gaps Higher After Touting 'Historic' And Unexpected Win In Breast Cancer
The company is testing a HER2 drug. It showed unexpected promise in some patients. 
Via Investor's Business Daily
Roche And AstraZeneca Settle Ultomiris Patent Lawsuit
Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly... 
Via Benzinga
AstraZeneca's Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting
AstraZeneca plc (NASDAQ: AZN) said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2... 
Via Benzinga
70 Firms Going Ex-Dividend Next Week, Including GlaxoSmithKline, Dow And AstraZeneca
Ex-dividend dates are important to dividend investors because one must own a stock prior to its ex-dividend date in order to be eligible to receive its next dividend. 
Via Talk Markets
GSK Halts Late-Stage RSV Vaccine Trial In Pregnant Women
GlaxoSmithKline plc (NYSE: GSK) has paused a late-stage trial of its respiratory syncytial virus (RSV) vaccine candidate in pregnant women based on safety... 
Via Benzinga
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO... 
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Can the formerly red-hot biotech segment return to its previous glory? 
Via Investor's Business Daily
Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: Reuters
According to officials and internal World Health Organization documents reviewed by Reuters, the relatively short shelf life of AstraZeneca Plc's (NASDAQ: AZN)... 
Via Benzinga
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna's Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hookipa Gets $15M Upfront Payment And Equity Investment From Gilead Following... 
Via Benzinga
A Peek Into The Markets: US Stock Futures Edge Higher Ahead Of Economic Data, Fed Minutes
Pre-open movers 
Via Benzinga
Why Are AstraZeneca Shares Trading Higher Today
Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease... 
Via Benzinga
AstraZeneca Stock Ranked No. 1 In Group; Recently Reported Record Sales, Strong Outlook
AstraZeneca reported record sales, and a bullish outlook. AstraZeneca stock is idling though amid market weakness. Setting up for run higher? 
Via Investor's Business Daily
Large Cap Biopharma- Well Positioned For Choppy Markets
If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets. 
Via Talk Markets
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
Stock Market Rally Stalls As Inflation, Treasury Yields Soar: Weekly Review
The stock market rally remains stuck in a recent range as the major indexes slashed weekly gains on hot inflation. Treasury yields surged. 
Via Investor's Business Daily
Two Insider Moonshots Rising on Sudden Buying
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future. 
Via InvestorPlace
42 Stocks Moving In Thursday's Mid-Day Session
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares climbed 63.3% to $3.45 following the company's recent uplisting to the Nasdaq. BRC Inc. (NYSE: BRCC) climbed 35.8... 
Via Benzinga
Seagen Crumbles With AstraZeneca Expected To Pressure Its New Drug
Seagen called for lower-than-expected 2022 sales of Tukysa, a breast cancer drug. 
Via Investor's Business Daily
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
49 50 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.